### Mortality outcomes with hydroxychloroquine and chloroquine 1 in COVID-19: an international collaborative meta-analysis of 2

#### randomized trials 3

4 Cathrine Axfors MD, PhDa,1,2, Andreas M. Schmitt MDa,3,4, Perrine Janiaud PhD3, Janneke van 't Hooft MD, PhD1,5, Sherief Abd-Elsalam MD, PhD6, Ehab F. Abdo MD, PhD7, Benjamin S. Abella 5 MD, MPhil<sup>8</sup>, Javed Akram MBBS, FRCP<sup>9</sup>, Ravi K. Amaravadi MD<sup>10</sup>, Derek C. Angus MD<sup>11,12</sup>, 6 7 Yaseen M. Arabi MD, FCCP, FCCM<sup>13</sup>, Shehnoor Azhar BDS, MPH<sup>14</sup>, Lindsey R. Baden MD<sup>15</sup>, 8 Arthur W. Baker MD, MPH<sup>16</sup>, Leila Belkhir MD, PhD<sup>17</sup>, Thomas Benfield MD, DMSc<sup>18</sup>, Marvin 9 A.H. Berrevoets MD<sup>19</sup>, Cheng-Pin Chen MD<sup>20</sup>, Tsung-Chia Chen MD<sup>21</sup>, Shu-Hsing Cheng MD, 10 PhD<sup>20</sup>, Chien-Yu Cheng MD<sup>20</sup>, Wei-Sheng Chung MD, PhD<sup>21</sup>, Yehuda Z. Cohen MD<sup>22</sup>, Lisa N. 11 Cowan MS<sup>22</sup>, Olav Dalgard MD, PhD<sup>23,24</sup>, Fernando F. de Almeida e Val PhD<sup>25</sup>, Marcus V.G. de 12 Lacerda PhD<sup>25,26</sup>, Gisely C. de Melo PhD<sup>25,27</sup>, Lennie Derde MD, PhD<sup>28,29</sup>, Vincent Dubee MD, 13 PhD<sup>30</sup>, Anissa Elfakir MSc<sup>31</sup>, Anthony C. Gordon MD<sup>32</sup>, Carmen M. Hernandez-Cardenas MD, MSc<sup>33</sup>, Thomas Hills DPhil<sup>34,35</sup>, Andy I.M. Hoepelman Prof. Dr.<sup>36</sup>, Yi-Wen Huang MD<sup>37</sup>, Bruno Igau 14 15 PhD<sup>22</sup>, Ronghua Jin MD, PhD<sup>38</sup>, Felipe Jurado-Camacho MD, MSc<sup>33</sup>, Khalid S. Khan MBBS, MRCOG<sup>39</sup>, Peter G Kremsner MD<sup>40,41,42</sup>, Benno Kreuels MD<sup>43,44</sup>, Cheng-Yu Kuo MD<sup>45</sup>, Thuy Le MD, 16 17 PhD<sup>16</sup>, Yi-Chun Lin MD<sup>20</sup>, Wu-Pu Lin MD<sup>46</sup>, Tse-Hung Lin MD<sup>37</sup>, Magnus Nakrem Lyngbakken MD, PhD<sup>47,24</sup>, Colin McArthur MBChB<sup>34,35,48</sup>, Bryan J. McVerry MD<sup>49</sup>, Patricia Meza-Meneses MD<sup>50</sup>, 18 19 Wuelton M. Monteiro PhD<sup>25,27</sup>, Susan C. Morpeth PhD<sup>51</sup>, Ahmad Mourad MD<sup>52</sup>, Mark J. Mulligan 20 MD, FIDSA<sup>53,54</sup>, Srinivas Murthy MD, MHSc<sup>55</sup>, Susanna Naggie MD<sup>16</sup>, Shanti Narayanasamy 21 MBBS<sup>16</sup>, Alistair Nichol PhD<sup>48,56,57,58</sup>, Lewis A. Novack MS<sup>59</sup>, Sean M. O'Brien PhD<sup>60</sup>, Nwora Lance 22 Okeke MD, MPH<sup>16</sup>, Léna Perez MS<sup>61</sup>, Rogelio Perez-Padilla MD<sup>62</sup>, Laurent Perrin MSc<sup>63</sup>, Arantxa 23 Remigio-Luna MD<sup>62</sup>, Norma E. Rivera-Martinez MD, MSc<sup>64</sup>, Frank W. Rockhold PhD<sup>60</sup>, Sebastian Rodriguez-Llamazares MD, MPH<sup>62</sup>, Robert Rolfe MD<sup>16</sup>, Rossana Rosa MD<sup>65</sup>, Helge Røsjø MD, 24 25 PhD<sup>66,24</sup>, Vanderson S. Sampaio PhD<sup>25,67</sup>, Todd B. Seto MD, MPH<sup>68,69</sup>, Muhammad Shehzad PhD<sup>70</sup>, NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. Shaimaa Soliman MD, PhD<sup>7</sup>, Jason E. Stout MD, MHS<sup>10</sup>, Ireri Thirion-Romero MD, MSC<sup>92</sup>, Andrea 26

1 B. Troxel ScD<sup>72</sup>, Ting-Yu Tseng MD<sup>21</sup>, Nicholas A. Turner MD, MHSc<sup>16</sup>, Robert J. Ulrich MD<sup>73</sup>, 2 Stephen R. Walsh MD<sup>15</sup>, Steve A. Webb MD, MPH, PhD<sup>48,74</sup>, Jesper M. Weehuizen MD<sup>36</sup>, Maria 3 Velinova MD, PhD<sup>75</sup>, Hon-Lai Wong MD<sup>76</sup>, Rebekah Wrenn PharmD<sup>16</sup>, Fernando G, Zampieri MD, 4 PhD<sup>77,78,79</sup>, Wu Zhong PhD<sup>80</sup>, David Moher PhD<sup>81</sup>, Steven N. Goodman MD, PhD<sup>1,82,83</sup>, John P.A. Ioannidis MD, DSc1,82,83,84,85, Lars G. Hemkens MD, MPH1,3,85 5 6 7 <sup>a</sup>Equal contributions, <sup>1</sup>Meta-Research Innovation Center at Stanford (METRICS), Stanford University, 8 Stanford, CA, USA, <sup>2</sup>Department for Women's and Children's Health, Uppsala University, Uppsala, 9 Sweden, <sup>3</sup>Department of Clinical Research, University Hospital Basel, University of Basel, Basel, 10 Switzerland, <sup>4</sup>Department of Medical Oncology, University of Basel, Basel, Switzerland, <sup>5</sup>Amsterdam 11 University Medical Center, Amsterdam University, Amsterdam, the Netherlands, 6Tropical Medicine 12 and Infectious Diseases Department, Faculty of Medicine, Tanta University, Tanta, Egypt, 7Tropical 13 Medicine and Gastroenterology Department, Faculty of Medicine, Assiut University, Assiut, Egypt, 14 <sup>8</sup>Department of Emergency Medicine, University of Pennsylvania, USA, <sup>9</sup>Department of Internal Medicine, Vice Chancellor, University of Health Sciences, Khayaban e Jamia Punjab, Lahore, Punjab, 15 16 54000, Pakistan, <sup>10</sup>Abramson Cancer Center and Department of Medicine, University of 17 Pennsylvania, Philadelphia, USA, <sup>11</sup>Department of Critical Care Medicine, The Clinical Research 18 Investigation and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh, 19 Pittsburgh, Pennsylvania, USA, <sup>12</sup>the UPMC Health System Office of Healthcare Innovation, 20 University of Pittsburgh Medical Centre, Pittsburgh, Pennsylvania, USA, <sup>13</sup>Intensive Care 21 Department, King Saud Bin Abdulaziz University for Health Sciences and King Abdullah 22 International Medical Research Center, Riyadh, Saudi Arabia, <sup>14</sup>Department of Public Health, 23 University of Health Sciences, Khavaban e Jamia Punjab, Lahore, Punjab, 54000, Pakistan, <sup>15</sup>Division 24 of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA, <sup>16</sup>Department of 25 Medicine, Division of Infectious Diseases and International Health, Duke University Medical Center, 26 Durham, NC, 27710, USA, <sup>17</sup>Infectious Diseases Department, Cliniques universitaires Saint-Luc, 27 Université Catholique de Louvain, Brussels, Belgium, <sup>18</sup>Center of Research & Disruption of 28 Infectious Diseases, Department of Infectious Diseases, Copenhagen University Hospital, Amager

and Hvidovre, Kettegaard Alle 30, Hvidovre, 2650, Denmark, <sup>19</sup>Department of Internal Medicine, 1 2 Elisabeth-Tweesteden hospital, Tilburg, the Netherlands, <sup>20</sup>Department of Infectious Diseases, 3 Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, 330, Taiwan, <sup>21</sup>Department of 4 Internal Medicine, Taichung Hospital, Ministry of Health and Welfare, Taichung, Taiwan, <sup>22</sup>Sanofi, 5 Bridgewater, NJ, USA, <sup>23</sup>Department of Infectious Diseases, Division of Medicine, Akershus 6 University Hospital, Lørenskog, Norway, <sup>24</sup>Institute of Clinical Medicine, Faculty of Medicine, 7 University of Oslo, Oslo, Norway, <sup>25</sup>Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, 8 Pedro Teixeira, 25, Manaus, AM, 69040-000, Brazil, <sup>26</sup>Instituto Leonidas e Maria Deane – ILMD, 9 FIOCRUZ-AM, Teresina, 476, Manaus, AM, 69.057-070, Brazil, <sup>27</sup>Universidade do Estado do 10 Amazonas, Djalma Batista, 2470, Manaus, AM, 69050-300, Brazil, <sup>28</sup>Julius Center for Health Science 11 and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands, <sup>29</sup>Intensive Care Centre, 12 University Medical Center Utrecht, Utrecht, Netherlands, <sup>30</sup>Infectious and Tropical Diseases 13 Department, Angers University Hospital, Angers, France, <sup>31</sup>Ividata Life Sciences, Levallois-Perret, 14 France, <sup>32</sup>Department of Surgery and Cancer, Anaesthetics, Pain Medicine, and Intensive Care 15 Medicine, Imperial College London and Imperial College Healthcare NHS Trust, London, United 16 Kingdom, <sup>33</sup>Critical Care Department, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío 17 Villegas, Mexico, <sup>34</sup>Medical Research Institute of New Zealand, Wellington, New Zealand, 18 <sup>35</sup>Auckland City Hospital, Auckland, New Zealand, <sup>36</sup>Department of Infectious Diseases, University 19 Medical Center Utrecht, Utrecht, the Netherlands, <sup>37</sup>Department of Internal Medicine, Chang Hua 20 Hospital, Ministry of Health and Welfare, Changhua, Taiwan, <sup>38</sup>Beijing Youan Hospital, Capital 21 Medical University, Beijing, P. R. China, <sup>39</sup>Department of Preventive Medicine & Public Health, 22 University of Granada, Hospital Real, Avenida del Hospicio, Granada, Granada, 18010, Spain, 23 <sup>40</sup>Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany, <sup>41</sup>Centre de Recherches 24 Médicales de Lambaréné, Lambaréné, Gabon, <sup>42</sup>German Center for Infection Research, Partner Site 25 Tübingen, Tübingen, Germany, <sup>43</sup>Department of Medicine, Division of Tropical Medicine and 26 Division of Infectious Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 27 <sup>44</sup>Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine, Hamburg, 28 Germany, <sup>45</sup>Department of Internal Medicine, Pingtung Hospital, Ministry of Health and Welfare,

1 Pingtung, Taiwan, <sup>46</sup>Department of Internal Medicine, Taipei Hospital, Ministry of Health and 2 Welfare, New Taipei City, Taiwan, <sup>47</sup>Division of Medicine, Akershus University Hospital, Lørenskog, 3 Norway, <sup>48</sup>School of Epidemiology and Preventive Medicine, Australian and New Zealand Intensive 4 Care Research Centre, Monash University, Melbourne, Victoria, Australia, <sup>49</sup>Department of Medicine, 5 University of Pittsburgh, Pittsburgh, Pennsylvania, USA, <sup>50</sup>Hospital Regional de Alta especialidad de 6 Ixtapaluca, Mexico, <sup>51</sup>Middlemore Hospital, Auckland, New Zealand, <sup>52</sup>Department of Medicine, 7 Duke University Medical Center, Durham, NC, 27710, USA, <sup>53</sup>Department of Microbiology, NYU 8 Grossman School of Medicine, 550 First Ave., New York, NY, 10016, USA, <sup>54</sup>Department of Internal 9 Medicine, Division of Infectious Diseases and Immunology, NYU Grossman School of Medicine, 550 10 First Ave., New York, NY, 10016, USA, <sup>55</sup>University of British Columbia School of Medicine, 11 Vancouver, British Columbia, Canada, <sup>56</sup>Department of Intensive Care, Alfred Health, Melbourne, 12 Victoria, Australia, <sup>57</sup>Department of Anesthesia and Intensive Care, St Vincent's University Hospital, 13 Dublin, Ireland, <sup>58</sup>School of Medicine and Medical Sciences, University College Dublin, Dublin, 14 Ireland, <sup>59</sup>Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, 15 Boston, MA, USA, <sup>60</sup>Department of Biostatistics and Bioinformatics, Duke University Medical 16 Center and Duke Clinical Research Institute, Durham, NC, 27710, USA, <sup>61</sup>Excelya, Montpellier, 17 France, <sup>62</sup>Department of Smoking and COPD, Instituto Nacional de Enfermedades Respiratorias 18 Ismael Cosío Villegas, Mexico, <sup>63</sup>Sanofi, Montpellier, France, <sup>64</sup>Hospital Regional de Alta 19 especialidad de Oaxaca, Mexico, <sup>65</sup>UnityPoint Health, Des Moines, IA, 50309, USA, <sup>66</sup>Division of 20 Research and Innovation, Akershus University Hospital, Lørenskog, Norway, <sup>67</sup>Fundação de 21 Vigilância em Saúde do Amazonas, Djalma Batista, 2470, Manaus, AM, 69093-018, Brazil, 22 <sup>68</sup>University of Hawaii John A. Burns School of Medicine, HI, USA, HI, USA, <sup>69</sup>The Queen's Medical 23 Center, Honolulu, HI, USA, <sup>70</sup>Department of Pharmacology, University of Health Sciences, Khayaban 24 e Jamia Punjab, Lahore, Punjab, 54000, Pakistan, <sup>71</sup>Public health and Community Medicine, Menoufia University, Menoufia, Egypt, 72Department of Population Health, Division of Biostatistics, 25 26 NYU Grossman School of Medicine, 180 Madison Avenue, Fifth Floor, 5-55, New york, NY, 10016, 27 USA, <sup>73</sup>Department of Medicine, Division of Infectious Diseases and Immunology, NYU Grossman 28 School of Medicine, 550 First Ave., New York, NY, 10016, USA, 74St. John of God Hospital,

Subiaco, Western Australia, Australia, <sup>75</sup> PRA Health Science, Groningen, Netherlands, <sup>76</sup> Department
of Internal Medicine, Keelung Hospital, Ministry of Health and Welfare, Keelung, Taiwan, 77Research
Institute, HCor-Hospital do Coração, São Paulo, São Paulo, Brazil, <sup>78</sup> Research Institute, BRICNet -
Brazilian Research in Intensive Care Network, São Paulo, São Paulo, Brazil, <sup>79</sup> IDor Research
Institute, São Paulo, São Paulo, Brazil, <sup>80</sup> National Engineering Research Center for the Emergency
Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, P. R. China, <sup>81</sup> Centre for
Journalology, Clinical Epidemiology Program, Ottawa Hospital Research Institute, 501 Smyth Road,
Ottawa K1H 8L6, Canada, 82Stanford University School of Medicine, Stanford, CA, USA,
<sup>83</sup> Department of Epidemiology and Population Health, Stanford University School of Medicine,
Stanford, CA, USA, <sup>84</sup> Stanford Prevention Research Center, Department of Medicine, Stanford
University, Stanford, CA, USA, <sup>85</sup> Meta-Research Innovation Center Berlin (METRIC-B), Berlin
Institute of Health, Berlin, Germany
Corresponding author:
Lars G. Hemkens, MD, MPH
Department of Clinical Research, University Hospital Basel, Spitalstrasse 12, CH-4031 Basel,
Switzerland
Phone: +41 61 265 3100, Mail: lars.hemkens@usb.ch

20 Word count: Main text: 2984. Abstract: 225.

#### Abstract 1

2	Background: Substantial COVID-19 research investment has been allocated to randomized clinical
3	trials (RCTs) on hydroxychloroquine/chloroquine, which currently face recruitment challenges or
4	early discontinuation. We aimed to estimate the effects of hydroxychloroquine and chloroquine on
5	survival in COVID-19 from all currently available RCT evidence, published and unpublished.
6	Methods: Rapid meta-analysis of ongoing, completed, or discontinued RCTs on hydroxychloroquine
7	or chloroquine treatment for any COVID-19 patients (protocol: https://osf.io/QESV4/). We
8	systematically identified published and unpublished RCTs by September 14, 2020 (ClinicalTrials.gov,
9	WHO International Clinical Trials Registry Platform, PubMed, Cochrane COVID-19 registry). All-
10	cause mortality was extracted (publications/preprints) or requested from investigators and combined
11	in random-effects meta-analyses, calculating odds ratios (ORs) with 95% confidence intervals (CIs),
12	separately for hydroxychloroquine/chloroquine. Prespecified subgroup analyses included patient
13	setting, diagnostic confirmation, control type, and publication status.
14	Results: Sixty-two trials were potentially eligible. We included 16 unpublished trials (1596 patients)
15	and 10 publications/preprints (6317 patients). The combined summary OR on all-cause mortality for
16	hydroxychloroquine was 1.08 (95%CI: 0.99, 1.18; I <sup>2</sup> =0%; 24 trials; 7659 patients) and for
17	chloroquine 1.77 (95%CI: 0.15, 21.13, I <sup>2</sup> =0%; 4 trials; 307 patients). We identified no subgroup
18	effects.
19	Conclusions: We found no benefit of hydroxychloroquine or chloroquine on the survival of COVID-
20	19 patients. For hydroxychloroquine, the confidence interval is compatible with increased mortality
21	(OR 1.18) or negligibly reduced mortality (OR 0.99). Findings have unclear generalizability to
22	outpatients, children, pregnant women, and people with comorbidities.
23	

24 Keywords: Meta-analysis, SARS-CoV-2, COVID-19, Hydroxychloroquine, Chloroquine

## 1 Introduction

2 Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 3 (SARS-CoV-2) has the potential of progression into respiratory failure and death.<sup>1</sup> More than 900,000 4 persons with COVID-19 globally have died by September, 2020,<sup>2</sup> and treatment options are limited.<sup>3</sup> 5 The COVID-19 pandemic has caused a hitherto unprecedented search for possible therapies, with 6 almost 700 clinical trials initiated in the first quarter of 2020 - and one in five of these trials target 7 hydroxychloroquine (HCQ) or chloroquine (CQ) (unpublished data). This remarkable attention was 8 primarily due to *in vitro* data,<sup>4</sup> immunomodulatory capacities,<sup>5</sup> and the oral formulation and well-9 documented safety profiles. In March 2020, the US Food and Drug Administration (FDA) issued an 10 Emergency Use Authorization of HCQ<sup>6</sup> and its prescription and usage outside clinical studies 11 skyrocketed.<sup>7</sup> In many countries, HCO or CO were listed in treatment guidelines for COVID-19 12 (including, e.g., China, Ireland, and the US).<sup>8</sup> In a New York City cohort of 1376 COVID-19 13 inpatients during March-April 2020, 59% received HCO.9 However, the FDA revoked the Emergency 14 Use Authorization on June 15, 2020.<sup>10</sup> At that point, two large randomized clinical trials (RCTs), 15 RECOVERY and the WHO Solidarity trial, had stopped enrollment to their HCQ treatment arms.<sup>11,12</sup> An interim analysis of the RECOVERY trial showed no mortality benefit of HCQ.<sup>12</sup> Established as 16 17 treatments of malaria and rheumatic disorders, HCQ and CQ may carry potentially severe adverse 18 effects, especially related to cardiac arrhythmia.<sup>5</sup> Public uncertainty still remains, as illustrated by 19 recent reports of planned use in pandemic epicenters in Central and South America.<sup>13</sup> 20 While many trials are ongoing, additional published evidence of potential benefits or harms may be 21 several months away, if they even reach completion. Given the lack of favorable results in the large 22 RECOVERY trial and the revoked Emergency Use Authorization, recruitment into HCQ and CQ 23 trials has become increasingly difficult and many trials may run the risk of ending in futility. A rapid 24 examination of data on all-cause mortality from as many trials as possible may offer the best evidence 25 on potential survival benefits and to ensure that patients are not exposed to unnecessary risks if 26 benefit is lacking. We used the infrastructure established with COVID-evidence,<sup>14</sup> a comprehensive 27 database of COVID-19 trials funded by the Swiss National Science Foundation, to invite all

investigators of HCQ or CQ trials to participate in an international collaborative meta-analysis. We
 aimed to identify and combine all RCTs investigating the effects of HCQ or CQ on all-cause mortality
 in patients with COVID-19 compared to any control arm similar to the experimental arm in all aspects
 except the administration of HCQ or CQ.

## 5 Methods

6 This collaborative meta-analysis, registered before data collection,<sup>15</sup> focused solely on all-cause
7 mortality in order to provide rapid evidence on the most critical clinical outcome. Investigators of
8 ongoing, discontinued or completed trials were contacted via email to provide group-level
9 (aggregated) mortality data per trial arm at any time point available.

10 We considered all clinical trials that reported randomly allocating patients with confirmed or 11 suspected SARS-CoV-2 infection to a treatment protocol containing HCO or CO (for any duration or 12 dose) or the same treatment protocol not containing HCQ or CQ. In other words, the control group 13 had to receive placebo or no treatment other than standard of care (we excluded comparisons of HCQ 14 or CQ against an active treatment, e.g., HCQ versus azithromycin, since active controls were too 15 heterogeneous to pool together and reveal the pure benefits and harms of HCQ or CQ). Eligible 16 ongoing trials had to provide data on all-cause mortality and randomize the first patient before June 1, 17 2020 (time point selected arbitrarily as we did not expect trials launched later to recruit enough 18 patients to provide relevant additional information). Trials published or posted as preprint were not 19 restricted by date. Prevention trials were not included. We included trials regardless of whether 20 mortality was a primary outcome or not and put no restrictions on trial status, language, geographical 21 region, or healthcare setting.

We searched for eligible trials registered at ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform [ICTRP] by June 11, 2020 (COVID-evidence database).<sup>16</sup> We additionally searched PubMed and the Cochrane COVID-19 trial registry (covering preprints, trial registries and literature databases) by June 11, 2020, using terms related to HCQ and CQ combined with terms for

1 COVID-19 and a standard RCT filter (Supplement 1).<sup>17</sup> We updated the literature search on

2 September 14, 2020. Two authors (CA and AMS) independently verified the eligibility criteria

3 (Figure 1) and solved any discrepancies by discussion.

Principal investigators of 83 potentially eligible trials were asked to confirm the eligibility criteria, as
well as: "For each of your study arms: (a) What intervention did this group receive? (b) How many
patients were randomized to this group? (c) Of these patients, how many have died? (d) Of these
patients, for how many it is unknown if they are dead or alive?" (Supplement 2, email template).
Investigators who were not responsive received two email reminders in English or Chinese,
depending on trial origin.

10 The following information was extracted from all included RCTs by two reviewers (CA, AMS) and 11 verified by the trial investigators: experimental and control arms, number of randomized participants, 12 treatment schedule, patient setting, eligibility criteria, study location, blinding, target sample size, and 13 trial status. We also classified trials as published in a peer-reviewed journal, posted on a preprint 14 server, or unpublished (the latter category not including preprints). For reasons of feasibility within 15 this rapid assessment, we generally did not request descriptive information beyond items included in 16 trial registrations.

17 The main analysis evaluated separately the effect on all-cause mortality of HCQ versus control and 18 CO versus control. We report absolute numbers and proportions, as well as the treatment effect 19 estimate as an odds ratio (OR; odds of death in the HCQ or CQ intervention group divided by the 20 odds of death in the control group) with 95% confidence intervals (CIs). For multi-arm studies, we 21 requested data for all arms and calculated treatment effect estimates for each eligible comparison. We 22 combined mortality effects from all RCTs based on binary outcome data (2x2 contingency tables) in meta-analyses and describe the statistical heterogeneity using the I<sup>2</sup>-statistic.<sup>18</sup> In our protocol, we 23 prespecified a random-effects model of the Hartung-Knapp-Sidik-Jonkman (HKSJ) approach,<sup>19</sup> in 24 25 order to provide more equality of weights between trials with moderate to large size (than for example 26 the DerSimonian-Laird approach). We did not prespecify the between-study variance estimator, tau-

1 squared, but chose the Paule and Mandel (PM) estimator based on provided guidance on choosing 2 among 16 variants.<sup>20</sup> Cases of zero events in one arm were corrected by adding the reciprocal of the 3 size of the contrasting study arm.<sup>17</sup> However, considering the range of sample sizes and numbers of 4 zero events across trials, we assessed the effects of alternative approaches with sensitivity analyses, as 5 detailed below. To explore and illustrate evidence generation over time, we also performed a 6 cumulative meta-analysis of all trials as well as stratified by dissemination status 7 (publications/preprints vs unpublished), using the HKSJ approach with PM tau-squared. We used the 8 date of email response or publication/posting of preprint. The meta-analyses were completed using R 9 version 3.5.1 and the 'meta' package version 4.13-0. 10 We stratified trials by patient setting (as proxy to COVID-19 severity: outpatients, inpatients but not 11 intensive care unit (ICU), and ICU), diagnostic confirmation (confirmed SARS-CoV-2 versus 12 suspected cases), control type (placebo control versus other) and publications/preprints versus 13 unpublished trials. We did not stratify for missing data since the amount was extremely low. A post-14 hoc stratification by HCQ dose was added (trials with  $\geq 1600$  mg on day 1 and  $\geq 800$  mg from day 2 15 versus lower-dose trials) to isolate trials predicted to achieve blood levels of HCO above the *in vitro* 16 half maximal inhibitory concentration (IC50) value for SARS-CoV-2 (1.13 µM).<sup>21</sup> 17 We added exploratory sensitivity analyses to assess robustness across meta-analytic approaches: 18 DerSimonian-Laird and Sidik-Jonkman tau-squared estimators, Mantel-Haenszel random-effects 19 method, and Peto method. DerSimonian-Laird is a standard random-effects meta-analysis approach, 20 but may underestimate uncertainty. The Sidik-Jonkman tau-squared estimator, on the other hand, may 21 yield inflated estimates if heterogeneity is low.<sup>20</sup> The Mantel-Haenszel method performs reasonably 22 well with small and zero event counts, much like Peto and arcsine transformation. The Peto method is 23 suboptimal in the presence of substantial imbalances in the allocation ratio of patients randomized in 24 the compared arms (e.g., RECOVERY trial). We also modeled variants to handling zero events 25 (arcsine difference, and excluding trials with zero events) as well as excluding trials with <5026 participants.

## 1 Results

2 Our search identified 146 randomized trials investigating HCQ or CQ as treatment for COVID-19, of 3 which 83 were deemed potentially eligible after scrutinizing the randomized comparisons. The 4 investigators of these 83 trials were contacted and 57% (47 of 83) responded (Figure 1). Of the 5 responders, 19 trials were eligible and available (16 unpublished and three preprints); 21 trials were 6 ineligible according to information provided; five responding investigator teams were not ready to 7 share their results yet; and two declined participation. For the 36 trials without response, five were 8 confirmed eligible and available (three publications and two preprints); two were confirmed 9 ineligible; and for the remaining 29, results were not available, nor could they be confirmed eligible. 10 Individual trial characteristics are presented in Table 1 (26 included trials) and Supplement Table S1 11 (36 potentially eligible but unavailable). Overall, trial characteristics were not different between 12 included and unavailable trials (Table 2).

13

14 We included 26 trials (Table 1; 16 unpublished trials, five publications, and five preprints; of these, 15 one publication and one preprint were identified in our search update). 12,22-30 HCQ was evaluated in 16 24 trials (7659 patients), and CQ was evaluated in four trials (307 patients). Two trials investigated 17 both HCQ versus control and CQ versus control (63 patients). The median sample size was 58 (IQR 18 24 to 207) for HCQ trials and 42 (IQR 35 to 234) for CQ trials. One very large trial (RECOVERY) 19 included 62% of all patients in the HCQ trials. Most trials investigated HCQ or CQ in hospitalized 20 patients (20 trials; 77%), and only five trials (19%) had an outpatient setting. The average mortality 21 was 10% (standard deviation 13%) in inpatient trials and 0.08% (standard deviation 0.18%) in 22 outpatient trials. The comparator was in eleven trials placebo (42%) and in 14 (54%) no other 23 treatment than standard of care. In most trials, patients and clinicians were aware of the treatment (13 24 trials; 50%), while in one trial (4%) the patients were blinded and in eleven trials (42%) patients and 25 clinicians were blinded (Table 2).

26

1	Regarding HCQ, in the 24 included trials, 499 of 3020 (16.5%) patients treated with HCQ died and
2	874 of 4639 patients (18.8%) in the control groups died. In the meta-analysis, the combined OR was
3	1.08 (95% CI, 0.99 to 1.18, $p = 0.07$ ), with low heterogeneity ( $I^2 = 0\%$ ) (Figure 2A). In 11 trials
4	including a total of 782 patients, there were zero deaths in both arms.
5	Regarding CQ, in the 4 included trials, 18 of 160 (11%) patients treated with CQ died and 12 of 147
6	patients (8%) in the control groups died. The combined OR was 1.77 (95% CI: 0.15 to 21.13, $p =$
7	0.21), with low heterogeneity ( $I^2 = 0\%$ ) (Figure 2B). In two of four trials including a total of 217
8	patients, there were zero deaths in both arms.
9	The available evidence in this study is the result of publications, preprints or personal communication
10	accrued over four months (from April 10, 2020 to August 12, 2020), with on average one trial added
11	every fifth day (Figure 3A-C).
12	
13	Results for the effects of HCQ on mortality were quite similar across subgroups (Supplement Table
14	S2A). When only including published information (publications and preprints, excluding unpublished
15	trials), there was a statistically significant harmful effect of HCQ (OR 1.10, 95% CI 1.07 to 1.13),
16	while among the unpublished trials there was no such conclusion of harm (OR 0.96, 95% CI 0.71

17 to 1.30, p for interaction = 0.320). We conducted no subgroup analyses for CQ, as there were only two

18 trials with events. In the sensitivity analyses employing different meta-analytical approaches

19 (Supplement Table S2B and Figures S1A-C), results were consistent.

## 1 Discussion

This collaborative meta-analysis of 26 published or unpublished RCTs, including 7966 patients, found
no overall survival benefit of HCQ or CQ as treatment options for COVID-19 patients. No differences
were seen across subgroup analyses on patient setting, diagnosis confirmation, control type,
publication status or dose. For CQ, the number of studies was too small to draw clear conclusions.

6

7 This meta-analysis offers useful insights for a challenging health situation. Hundreds of thousands of 8 patients have received HCQ and CQ outside of clinical trials without evidence of their beneficial 9 effects. Public interest is unprecedented, with weak early evidence supporting HCQ's merits being 10 widely discussed in some media and social networks - despite the unfavorable results by a very large 11 RCT. Numerous clinical studies have been investigating HCQ and CQ almost simultaneously. 12 Although seven systematic reviews and meta-analyses are already available, they only consider the 13 small handful of RCTs being already published (which were all included here).<sup>31–35</sup> While data 14 sharing has been rather limited to-date in biomedical research, such openness can be transformative in 15 generating knowledge. This pandemic has brought together a collaboration of clinical trialists 16 agreeing to share their data, which allows this study to not only summarize the existing evidence, but 17 also illustrate the accumulation of evidence that would otherwise not be available.

18

For HCQ, evidence is dominated by the RECOVERY trial,<sup>12</sup> which indicated no mortality benefit for 19 20 treated COVID-19 patients, together with longer hospitalization and higher risk of progression to 21 invasive mechanical ventilation and/or death. Adding the few other available publications or 22 preprints, one would have concluded a statistically significant increased mortality in COVID-19 23 patients treated with HCQ. Considering also the unpublished data, which tend towards a null effect, 24 this meta-analysis' confidence intervals are compatible with increased mortality (OR 1.18) or 25 negligibly reduced mortality (OR 0.99). The tendency of published trials to report larger effect sizes 26 than unpublished trials is well-documented and constitute one of the reporting biases that are 27 discernable only when a body of studies are considered together.<sup>36</sup> Null results are less expected to be

1	rapidly disseminated, especially if the trial is small. Of note, RECOVERY results showing
2	dexamethasone benefits have been published more rapidly <sup>3</sup> than the unfavorable HCQ results. <sup>12</sup> This
3	paper offers the most comprehensive summary on HCQ and mortality in COVID-19 to date.
4	

5 This meta-analysis does not address prophylactic use nor other outcomes besides mortality. Also, 6 generalizability is unclear for certain populations. All but three trials excluded children and the 7 majority excluded pregnant or breastfeeding women. Among five studies on outpatients, there were 8 three deaths, two occurring in the one trial of 491 relatively young patients with few comorbidities,<sup>24</sup> 9 and one occurring in a small trial with 27 patients. For outpatients that are elderly or have 10 comorbidities, evidence is sparse. Most of the 26 trials excluded persons with comorbid conditions 11 carrying higher risk of adverse events from HCQ/CQ.<sup>22-24</sup> No evidence is in the pipeline for these 12 groups, which echoes clinical reasoning being reluctant to expose them to risk.

13

Twenty percent of the potentially eligible trials were listed as discontinued, mostly because of fewer patients than expected. Among 26 included RCTs, only two had reached their target sample size at the time of censoring for this meta-analysis. As previously discussed,<sup>4</sup> most trials on HCQ and CQ in COVID-19 are small, reflecting both the strong motivation for individual efforts and underscoring the need for readily available research infrastructure to merge small-scale initiatives (unpublished data). Especially in the context of recruitment challenges, we encourage other researchers to form collaborations and combine trial results.<sup>37</sup>

21

Our analysis has some limitations. First, although we adopted a comprehensive, systematic search strategy, our real-time initiative differs from traditional systematic reviews. We focused on collecting unpublished information, aiming to rapidly secure as much trial evidence as possible. We did not review individual trials, nor break down results according to patient characteristics. Such analyses are planned in future publications using in-depth details disclosed in individual trial publications to come.<sup>38-40</sup> However, consistent findings in placebo-controlled, double-blinded and open-label trials indicate an overall low risk of bias across trials; moreover, attrition was negligible (median 0%, IQR

1 0% to 0%; range 0 to 19.5%). Meta-epidemiological work shows that mortality results are least 2 affected by lack of blinding, or problems in randomization and allocation concealment as compared 3 with other outcomes.<sup>41</sup> Second, a majority of the potentially eligible trials were not available. Despite 4 going far beyond the standard review of published evidence, we expect additional results from future 5 trials to narrow the uncertainty of the treatment effect and possibly reveal benefits or harms not 6 discernible based on the current evidence. Of the unavailable trials, the WHO Solidarity trial may 7 have the largest sample size and provide most mortality data. We plan to perform an update when 8 substantial additional evidence becomes available. Finally, although conclusions were robust across 9 sensitivity analyses addressing model specifications, one combination (HKSJ model with SJ tau-10 squared estimator) yielded substantially wider confidence intervals. This combination gave 11 disproportionately low weight to RECOVERY (16%) and we consider the main model (HKSJ with 12 PM tau-squared estimator) to be more valid in this situation.

13

Treatment with HCQ or CQ for COVID-19 showed no survival benefit based on currently available data. Medical professionals around the globe are encouraged to inform patients that HCQ should not be looked upon as a cure of COVID-19. Physicians who choose to prescribe HCQ for COVID-19 do so with very sparse evidence and need to consider the risk they are exposing their patients to without known concomitant benefit. Additional trials may solidify or modify the current picture of the evidence on these treatment options.

## 1 Declarations

### 2 Availability of data and materials

3 All data generated or analysed during this study are included in this published article and its4 supplementary information files.

### 5 Competing interests

6 Benjamin Abella and Ravi Amaravadi are the primary investigators of the Prevention and Treatment 7 of COVID19 with Hydroxychloroquine (PATCH) trial, funded by a philanthropic gift. Ravi 8 Amaravadi reports being founder with equity of Pinpoint Therapeutics and Immunacell, and personal 9 fees from Sprint Biosciences and Deciphera, outside the submitted work. Derek Angus reports 10 personal fees from Ferring Pharmaceuticals, Inc., Bristol-Myers Squibb, and Bayer AG, other from 11 Alung Technologies, Inc., outside the submitted work; in addition, Dr. Angus has pending patents for 12 Selepressin - compounds, compositions and methods for treating sepsis to Ferring, B.V., and 13 Proteomic biomarkers of sepsis in elderly patients pending to University of Pittsburgh. Yaseen Arabi 14 reports that he is principal investigator on a clinical trial of lopinavir-ritonavir and interferon for 15 Middle East respiratory syndrome (MERS) and that he was a non-paid consultant on therapeutics for 16 MERS-coronavirus (CoV) for Gilead Sciences and SAB Biotherapeutics. He is a co-investigator on 17 the Randomized, Embedded, Multi-factorial Adaptive Platform Trial for Community-Acquired 18 Pneumonia (REMAP-CAP), a board member of the International Severe Acute Respiratory and 19 Emerging Infection Consortium (ISARIC), and the Lead-Co Chair of the Think20 (T20) Taskforce for 20 COVID-19. Brigham and Women's Hospital, PRA Health Science, and Cliniques universitaires Saint-21 Luc received funds from Sanofi. Thomas Benfield reports grants from Pfizer, Novo Nordisk 22 Foundation, Simonsen Foundation, Lundbeck Foundation, and Kai Hansen Foundation; grants and 23 personal fees from GSK. Pfizer, Boehringer Ingelheim, and Gilead; and personal fees from MSD, all 24 outside the submitted work. Yehuda Cohen, Lisa Cowan, Bruno Igau, and Laurent Perrin are 25 employees of Sanofi. The COV-HCQ and COMIHY trials were supported by the German Federal 26 Ministry of Education and Research (EudraCT number 2020-001224-33) and the German Federal

Ministry of Health (EudraCT number 2020-001512-26). Lennie Derde reports grants from EU FP7-1 2 HEALTH-2013-INNOVATION-1, grant number 602525, grants from H2020 RECOVER grant 3 agreement No 101003589, during the conduct of the study; and is a member of the COVID-19 4 guideline committee SCCM/ESICM/SSC, member of the ESICM COVID-19 taskforce, and chair of 5 the Dutch intensivists (NVIC) taskforce infectious threats. Vincent Dubee reports non-financial 6 support from MSD France and from Sanofi Aventis France, outside the submitted work. Anissa 7 Elfakir is an employee of Ividata Life Sciences and works as an external contractor for Sanofi. 8 Anthony Gordon received grant funding from a NIHR Research Professorship (RP-2015-06-18), 9 support from the NIHR Imperial Biomedical Research Centre, and consulting fees paid to his 10 institution from GlaxoSmithKline and Bristol Myers Squibb. Thomas Hills reports grants from the 11 Health Research Council of New Zealand, during the conduct of the study. Andy Hoepelman reports 12 grants from ZonMw, Netherlands organisation for Health Research and Development, during the 13 conduct of the study. HYDRA trial was an investigator-initiated study supported by Sanofi, 14 CONACYT (National Council of Science and Technology of Mexico) and by the participating 15 centers. Thuy Le reports grants from Gilead Sciences, outside the submitted work. Bryan McVerry 16 reports grants from NIH/NHLBI, and from Bayer Pharmaceuticals, Inc., outside the submitted work. 17 Srinivas Murthy receives funding as the Innovative Medicines Canada Chair in Pandemic 18 Preparedness. Colin McArthur reports grants from the Health Research Council of New Zealand. 19 Mark Mulligan reports having received the HCQ drug from the New York State government, during 20 the conduct of the study; grants from Lilly, Pfizer, Sanofi, and personal fees from Meissa, outside the 21 submitted work; in addition, Dr. Mulligan has a patent anti-Zika monoclonal ab/ Emory Univ 22 pending. Alistair Nichol is supported by a Health Research Board of Ireland Clinical Trial Network 23 Award (HRB-CTH-2014-012). Lena Perez is an employee of Excelya and works as an external 24 contractor for Sanofi. Frank Rockhold reports personal fees from Merck Research Labs, Novartis, 25 Lilly, Sanofi, NovoNordisk, KLSMC, Tolerion, Rhythm, UCB, AstraZeneca, Janssen, Merck KGaA, 26 Sarepta, Eidos, Amgen, Phathom, outside the submitted work; and having equity interest in 27 GlaxoSmithkline, Athira Pharma, DataVant, Spencer Healthcare. Stephen Walsh reports receiving a 28 grant from Sanofi during the conduct of the study and grants from NIH-NIAID outside the submitted

1 work, and having conducted vaccine (HIV, Zika) clinical trials funded by Janssen. Steve Webb 2 reports grants from National Health and Medical Research Council (Australia), grants from Minderoo 3 Foundation, from Health Research Council (New Zealand), and from Medical Research Future Fund 4 (Australia), during the conduct of the study. Jesper Weehuizen reports grants from ZonMw, 5 Netherlands organisation for Health Research and Development, during the conduct of the study. 6 Fernando Zampieri was part of the Coalition 1 trial partially supported by EMS Pharmaceuticals, has 7 received previous grants from Bactiguard, Sweden, outside the submitted work and support from 8 Baxter LA for another clinical trial in critically ill patients. 9 None of the other authors have any competing interests to declare.

### 10 Funding

11 This collaborative meta-analysis was supported by the Swiss National Science Foundation and Laura 12 and John Arnold Foundation (grant supporting the post-doctoral fellowship at the Meta-Research 13 Innovation Center at Stanford (METRICS), Stanford University). Funding also includes postdoctoral 14 grants from Uppsala University, the Swedish Society of Medicine, the Blanceflor Foundation and the 15 Sweden-America Foundation (C. Axfors). The funders had no role in the design of this collaborative 16 meta-analysis; in the collection, analysis, and interpretation of data; or in the report writing. The 17 corresponding author had full access to all study data and final responsibility for the decision to 18 submit for publication.

### 19 Authors' contributions

20 Lars G. Hemkens, Cathrine Axfors and Andreas M. Schmitt had full access to all data in this study

- and take responsibility for the integrity of the data and the accuracy of the data analysis.
- 22 Concept and design: Lars G. Hemkens, John P. A. Ioannidis, Cathrine Axfors, Andreas M. Schmitt,
- 23 Steven N. Goodman, David Moher
- 24 Acquisition, analysis, or interpretation of data: All authors
- 25 Drafting of the manuscript: Cathrine Axfors, Andreas M. Schmitt, Lars G. Hemkens
- 26 Critical revision of the manuscript for important intellectual content: All authors

- 1 Statistical analysis: Andreas M. Schmitt, Lars G. Hemkens, John P. A. Ioannidis, Steven N.
- 2 Goodman, Perrine Janiaud
- 3 Approval of the final manuscript: All authors
- 4 Obtained funding: Lars G. Hemkens, Cathrine Axfors, John P. A. Ioannidis
- 5 Administrative, technical, or material support: Cathrine Axfors, Andreas M. Schmitt, Lars G.
- 6 Hemkens, Perrine Janiaud, Janneke van 't Hooft
- 7 Supervision: Lars G. Hemkens

#### 8 Acknowledgements

9 We wish to express our heartfelt gratitude to all patients volunteering for the trials involved. We 10 furthermore thank Wenvan Ma and Benjamin Kasenda (University Hospital Basel, University of 11 Basel) for kindly translating the emails to Chinese investigators. For valuable contributions to 12 individual trials in this collaborative group, we sincerely thank: Hannah Jin, Monica Feeley, Bruce 13 Bausk, Jessica Cauley, Jane Kleinjan, Jon Gothing, Naeema Bangash, Heather Wroe, Claire Bigogne, 14 Christelle Castell, Annelies Mottart, Lisette Cortenraad, Judith Medema-Muller, Katia Handelberg, 15 Khalid Benhammou, Shaheen Kumar, Sophie Gribomont, Kim Kuehne, Cathia Markina, Julien 16 Labeirie, Julie Pencole, Eva Crispyn, Cecile Le Breton, Kelli Horn, Tina Patel, Benjamin Harrois, 17 Isabelle Collin, Vetheeswar Manivannan, Irma Slomp, Frederick Becue, Isabelle Godefroy, Lynne 18 Guo, Lene Kollmorgen, Toluwalope Cole, Catherine Chene, Praveena Deenumsetti, Anne Doisy, 19 Ariane Vialfont, Melissa Charbit, Christine Shu, Stephane Kirkesseli, Howard Surks, Magalie De 20 Meyer, Edel Hendrickx, and Paul Deutsch (Sanofi trial); Ellie Carmody, Märtin Backer, Jaishvi 21 Eapen, Jack A. DeHovitz, Prithiv J. Prasad, Yi Li, Camila Delgado, Morris Jrada, Gabriel A. Robbins, 22 Brooklyn Henderson, Alexander Hrycko, Dinuli Delpachitra, Vanessa Raabe, Jonathan S. Austrian, 23 and Yanina Dubrovskaya (TEACH trial); Farah Al-Beidh, Djillali Annane, Kenneth Baillie, Abigail 24 Beane, Richard Beasley, Zahra Bhimani, Marc Bonten, Charlotte Bradbury, Frank Brunkhorst, 25 Meredith Buxton, Allen Cheng, Menno de Jong, Eamon Duffy, Lise Estcourt, Rob Fowler, Timothy 26 Girard, Herman Goossens, Cameron Green, Rashan Haniffa, Christopher Horvat, David Huang, 27 Francois Lamontagne, Patrick Lawler, Kelsey Linstrum, Edward Litton, John Marshall, Daniel

- 1 McAuley, Shay McGuinness, Stephanie Montgomery, Paul Mouncey, Katrina Orr, Rachael Parke,
- 2 Jane Parker, Asad Patanwala, Kathryn Rowan, Marlene Santos, Christopher Seymour, Steven Tong,
- 3 Anne Turner, Timothy Uyeki, Wilma van Bentum-Puijk, Frank van de Veerdonk, and Ryan
- 4 Zarychanski (REMAP-CAP trial); Jan-Erik Berdal, Arne Eskesen, Dag Kvale, Inge Christoffer Olsen,
- 5 Corina Silvia Rueegg, Anbjørg Rangberg, Christine Monceyron Jonassen, and Torbjørn Omland (NO
- 6 COVID-19 Trial). Support for title page creation and format was provided by AuthorArranger, a tool
- 7 developed at the National Cancer Institute.

# 1 References

2	1	Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med 2020; published online
3		May 15. DOI:10.1056/NEJMcp2009575.
4	2	COVID-19 Map. Johns Hopkins Coronavirus Resource Center.
5		https://coronavirus.jhu.edu/map.html (accessed Sep 16, 2020).
6	3	RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in Hospitalized
7		Patients with Covid-19 - Preliminary Report. N Engl J Med 2020; published online July 17.
8		DOI:10.1056/NEJMoa2021436.
9	4	Fantini J, Di Scala C, Chahinian H, Yahi N. Structural and molecular modelling studies reveal a
10		new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2
11		infection. Int J Antimicrob Agents 2020; 55: 105960.
12	5	dos Reis Neto ET, Kakehasi AM, de Medeiros Pinheiro M, et al. Revisiting hydroxychloroquine
13		and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases.
14		Advances in Rheumatology 2020; 60: 32.
15	6	Office of the Commissioner. Emergency Use Authorization. U.S. Food and Drug Administration.
16		2020; published online June 15. https://www.fda.gov/emergency-preparedness-and-
17		response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization (accessed
18		Aug 8, 2020).
19	7	Vaduganathan M, van Meijgaard J, Mehra MR, Joseph J, O'Donnell CJ, Warraich HJ.
20		Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the
21		United States. JAMA 2020; published online May 28. DOI:10.1001/jama.2020.9184.
22	8	Dagens A, Sigfrid L, Cai E, et al. Scope, quality, and inclusivity of clinical guidelines produced
23		early in the covid-19 pandemic: rapid review. BMJ 2020; 369: m1936.

1	9	Geleris J, Sun Y, Platt J, et al. Observational Study of Hydroxychloroquine in Hospitalized
2		Patients with Covid-19. N Engl J Med 2020; published online May 7.
3		DOI:10.1056/NEJMoa2012410.
4	10	Office of the Commissioner. Coronavirus (COVID-19) Update: FDA Revokes Emergency Use
5		Authorization for Chloroquine and Hydroxychloroquine. U.S. Food and Drug Administration.
6		2020; published online June 15. https://www.fda.gov/news-events/press-
7		announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-
8		chloroquine-and (accessed Aug 8, 2020).
9	11	WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19.
10		https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-
11		lopinavir-ritonavir-treatment-arms-for-covid-19 (accessed Aug 1, 2020).
12	12	Horby P, Mafham M, Linsell L, et al. Effect of Hydroxychloroquine in Hospitalized Patients
13		with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial. medRxiv
14		2020; published online July 15. DOI:10.1101/2020.07.15.20151852.
15	13	Trigo MS, Kurmanaev A, Cabrera JML. With Officials' Backing, Dubious Virus Remedies
16		Surge in Latin America. The New York Times. 2020; published online July 23.
17		https://www.nytimes.com/2020/07/23/world/americas/chlorine-coronavirus-bolivia-latin-
18		america.html (accessed Aug 6, 2020).
19	14	Janiaud P, Axfors C, Saccilotto R, Hemkens L. COVID-evidence: a living database of trials on
20		interventions for COVID-19. 2020. DOI:10.17605/OSF.IO/GEHFX.
21	15	Axfors C, Schmitt A, Janiaud P, et al. Hydroxychloroquine and chloroquine for survival in
22		COVID-19: an international collaborative meta-analysis of randomized trials. 2020.
23		DOI:10.17605/OSF.IO/QESV4.
24	16	COVID-evidence. https://covid-evidence.org/ (accessed Aug 24, 2020).

- 1 17 Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of
- 2 Interventions. John Wiley & Sons, 2019.
- 3 18 Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses.
  4 *BMJ* 2003; **327**: 557–60.
- 5 19 IntHout J, Ioannidis JPA, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random
- 6 effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian7 Laird method. *BMC Med Res Methodol* 2014; 14: 25.
- 8 20 Veroniki AA, Jackson D, Viechtbauer W, *et al.* Methods to estimate the between-study variance
  9 and its uncertainty in meta-analysis. *Res Synth Methods* 2016; 7: 55–79.
- 10 21 White NJ, Watson JA, Hoglund RM, Chan XHS, Cheah PY, Tarning J. COVID-19 prevention
- 11 and treatment: a critical analysis of chloroquine and hydroxychloroquine clinical pharmacology.
- 12 2020; published online June 20. https://www.tropmedres.ac/news/covid-19-prevention-and-
- 13 treatment-a-critical-analysis-of-chloroquine-and-hydroxychloroquine-clinical-pharmacology.
- 14 22 Chen L, Zhang Z-Y, Fu J-G, et al. Efficacy and safety of chloroquine or hydroxychloroquine in
- 15 moderate type of COVID-19: a prospective open-label randomized controlled study. Infectious
- 16 Diseases (except HIV/AIDS). 2020; published online June 22.
- 17 DOI:10.1101/2020.06.19.20136093.
- Tang W, Cao Z, Han M, *et al.* Hydroxychloroquine in patients with mainly mild to moderate
  coronavirus disease 2019: open label, randomised controlled trial. *BMJ* 2020; **369**: m1849.
- 24 Skipper CP, Pastick KA, Engen NW, *et al.* Hydroxychloroquine in Nonhospitalized Adults With
  21 Early COVID-19: A Randomized Trial. *Ann Intern Med* 2020; published online July 16.
  22 DOI:10.7326/M20-4207.
- 23 25 Jun C, Danping LIU, Li LIU, *et al.* A pilot study of hydroxychloroquine in treatment of patients
  24 with moderate COVID-19. *J Zhejiang Univ* 2020; 49: 215–9.

1	26	Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without
2		Azithromycin in Mild-to-Moderate Covid-19. N Engl J Med 2020; published online July 23.
3		DOI:10.1056/NEJMoa2019014.
4	27	Mitjà O, Corbacho-Monné M, Ubals M, et al. Hydroxychloroquine for Early Treatment of
5		Adults with Mild Covid-19: A Randomized-Controlled Trial. Clin Infect Dis 2020; published
6		online July 16. DOI:10.1093/cid/ciaa1009.
7	28	Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19:
8		results of a randomized clinical trial. <i>medRxiv</i> 2020; : 2020.03.22.20040758.
9	29	Lyngbakken MN, Berdal J-E, Eskesen A, et al. A pragmatic randomized controlled trial reports
10		the efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics. In Review. 2020;
11		published online July 17. DOI:10.21203/rs.3.rs-44055/v1.
12	30	Chen C-P, Lin Y-C, Chen T-C, et al. A Multicenter, randomized, open-label, controlled trial to
13		evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult
14		patients with mild to moderate Coronavirus disease 2019 (COVID-19). medRxiv 2020; :
15		2020.07.08.20148841.
16	31	Siemieniuk RA, Bartoszko JJ, Ge L, et al. Drug treatments for covid-19: living systematic
17		review and network meta-analysis. BMJ 2020; <b>370</b> : m2980.
18	32	Thoguluva Chandrasekar V, Venkatesalu B, Patel HK, Spadaccini M, Manteuffel J, Ramesh M.
19		Systematic review and meta-analysis of effectiveness of treatment options against SARS-CoV-2
20		infection. J Med Virol 2020; published online July 15. DOI:10.1002/jmv.26302.
21	33	Liu W, Zhou P, Chen K, et al. Efficacy and safety of antiviral treatment for COVID-19 from
22		evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and
23		meta-analysis. CMAJ 2020; 192: E734–44.
24	34	Hernandez AV, Roman YM, Pasupuleti V, Barboza JJ, Michael White C. Hydroxychloroquine

1		or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review. Ann
2		Intern Med https://www.acpjournals.org/doi/10.7326/M20-2496?url_ver=Z39.88-
3		2003𝔯_id=ori:rid:crossref.org𝔯_dat=cr_pub%20%200pubmed (accessed Aug 10, 2020).
4	35	Sarma P, Kaur H, Kumar H, et al. Virological and clinical cure in COVID-19 patients treated
5		with hydroxychloroquine: A systematic review and meta-analysis. J Med Virol 2020; 92: 776-
6		85.
7	36	Dechartres A, Atal I, Riveros C, Meerpohl J, Ravaud P. Association Between Publication
8		Characteristics and Treatment Effect Estimates: A Meta-epidemiologic Study. Ann Intern Med
9		2018; <b>169</b> : 385–93.
10	37	Petkova E, Antman EM, Troxel AB. Pooling Data From Individual Clinical Trials in the
11		COVID-19 Era. JAMA 2020; published online July 22. DOI:10.1001/jama.2020.13042.
12	38	Bravo-Jeria R, Rojas Reyes MX, Franco JVA, Paz Acuña M, Torres Lopez LA, Rada G.
13		Chloroquine and hydroxychloroquine for the treatment of COVID-19: a living systematic
14		review. PROSPERO 2020 CRD42020178195 2020; published online April 7.
15		https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=178195.
16	39	Scott DA, Khunti K, Gillies C, Seidu S, Coles B, Zaccardi F. A systematic review and meta-
17		analysis of the efficacy and safety of chloroquine for the treatment of patients with COVID-19.
18		PROSPERO 2020 CRD42020178266 2020; published online April 6.
19		https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=178266.
20	40	Fontes LE, Riera R, Martimbianco ALC, et al. Chloroquine/hydroxychloroquine for coronavirus
21		disease 2019 (COVID-19) - a systematic review of individual participant data. PROSPERO 2020
22		CRD42020178667
23		https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020178667.
24	41	Savović J, Jones HE, Altman DG, et al. Influence of reported study design characteristics on
25		intervention effect estimates from randomized, controlled trials. Ann Intern Med 2012; 157: 429-

1 38.

# Tables

Table 1. Group-level characteristics of randomized clinical trials evaluating hydroxychloroquine or chloroquine as treatment for COVID-19.

Acronym	Register ID	Treatment com	parison	Treatment schedule	Setting	Age	Mortality (%)	Location	Blinding	Targeted sample size	Status
		Experimental arm (n)	Control arm(n)								
Published****											
-	ChiCTR2000029559	HCQ (31)	No Treatment (31)	200 mg twice a day for 5 days	Inpatient	≥18 years	0	China	Participant, Caregiver	300	Completed
-	ChiCTR2000029868	HCQ (75)	No Treatment (75)	1200 mg/day for 3 days, then 800 mg/day for 11-18 days	Inpatient	≥18 years	0	China	None	360	Completed
-	NCT04261517	HCQ (15)	No Treatment (15)	400 mg/day for 5 days	Inpatient	≥18 years	0	China	None	30	Completed
RECOVERY	NCT04381936	HCQ (1561)	No Treatment (3155)	800 mg at zero hours, then 800 mg after 6 hours, then 800 mg/day for up to 9 days	Inpatient	≥18 years	25.57	United Kingdom	None	12000*	Completed **
	CI : CTTD 2000 2005 4	HCQ (18)	No Treatment (12)	400 mg/day for 10 days	T	18 to 75	0		None	100	
-	ChiCTR2000030054	CQ (18)	No Treatment (12)	1000 mg/day for 1 day, then 500 mg/days for 9 days	- Inpatient	years	0	- China		100	Completed
NO COVID-19	NCT04316377	HCQ (27)	No Treatment (26)	800 mg/day for 7 days	Inpatient	≥18 years	3.77	Norway	None	202	Halted
-	NCT04384380	HCQ (21)	No Treatment (12)	800 mg/day for 1 day, then 400 mg/day for 6 days	Inpatient	20 to 79 years	0	Taiwan	None	45	Recruiting
COVID-PEP	NCT04308668	HCQ (244)	Placebo (247)	800 mg at zero hours, then 600 mg after 6-8 hours, then 600 mg daily for 4 days	Outpatient	≥18 years	0.41	International ***	Participant, Caregiver	3000	Completed
BCN PEP CoV-2	NCT04304053	HCQ (136)	No Treatment (157)	800mg on day 1, and 400mg/day on days 2-7	Outpatient	≥18 years	0	Spain	None	2300	Completed
Coalition I	NCT04322123	HCQ (221)	No Treatment (227)	800 mg/day for 7 days	Inpatient	≥18 years	2.90	Brazil	None	630*	Halted

#### Unpublished\*\*\* \*

Ŧ											
РАТСН	NCT04329923	HCQ (15)	Placebo (15)	800 mg/day for up to 14 days	Inpatient	≥40 years	0	United States	Participant, Caregiver	400*	Recruiting
CCAP-1	NCT04345289	HCQ (1)	Placebo (1)	600 mg/day for 7 days	Inpatient	≥18 years	0	Denmark	Participant, Caregiver	1500*	Discont.
		HCQ (4)	No Treatment (2)	- 800 mg/day for 1 day, then 600			16.67				
-	NCT04335552	HCQ + Azithromycin (2)	Azithromycin (3)	mg/day for 4 days	Inpatient	≥12 years	60	United States	None	500	Discont.
ADCUAIC	NI 0400	CQ (5)	No Treatment (3)	600 mg at zero hours, then 300 mg after 12 hours, then 600 mg/day for 4 days	To a disad	. 10	12.50	Nole Lee L	None	050	
ARCHAIC	NL8490	HCQ (4)	No Treatment (3)	800 mg/day for 1 day, then 400 mg/day for 4 days	- Inpatient	≥18 years	28.57	<ul> <li>Netherlands</li> </ul>		950	Discont.
	NCT04342650	CQ (78)	Placebo (74)	900 mg/day for 1 day, then 450 mg/day for 4 days	Outpatient	≥18 years	0	Brazil	Participant, Caregiver	210	Completed
CloroCOVID19II	NCT04323527	CQ (41)	Placebo (41)	900 mg/day for 1 day, then 450 mg/day for 4 days	Inpatient	≥18 years	35.37	Brazil	Participant, Caregiver	278	Completed
HYDRA	NCT04315896	HCQ (75)	Placebo (77)	400 mg/day for 10 days	Inpatient	18 to 80 years	37.50	Mexico	Participant, Caregiver	500	Recruiting
-	ChiCTR2000031204	CQ (18)	Placebo (17)	1000 mg on day 1, then 500 mg/day on days 2-3, then 250 mg/day until ≤14 days of total treatment	Inpatient	18 to 70 years	0	China	Participant	300	Recruiting
-	NCT04333654	HCQ (5)	Placebo (3)	800 mg at zero hours, then 400 mg 6-8 hours later, then 600 mg/day for 9 days	Outpatient	18 to 80 years	0	International ***	Participant, Caregiver	210	Discontinu ed
-	NCT04353336	HCQ (97)	No Treatment (97)	800 mg/day on day 1, then 400 mg/day for 14 days	Inpatient	All	5.67	Egypt	None	40	Recruiting
		HCQ + Azithromycin + Oseltamivir (64)	Azithromycin + Oseltamivir (64)				0				
PROTECT	NCT04338698	HCQ + Oseltamivir (62)	Oseltamivir (63)	600 mg/day for 5 days	Inpatient	≥18 years	0.80	Pakistan	Investigator	500	Recruiting
		HCQ + Azithromycin (59)	Azithromycin (61)				2.50	-			

TEACH	NCT04369742	HCQ (67)	Placebo (61)	800 mg/day on day 1, then 400 mg/day for 4 days	Inpatient	All	10.16	United States	Participant, Caregiver	626	Discont.
OAHU-COVID19	NCT04345692	HCQ (10)	No Treatment (6)	800 mg/day on day 1, then 400 mg/day for 4 days	Inpatient	18 to 95 years	12.50	United States	None	350	Recruiting
REMAP-CAP	NCT02735707	HCQ (61)	No Treatment (81)	800 mg at zero and six hours, then 800 mg/day for up to 6 days	ICU	≥18 years	27.46	International ***	None	No fixed target sample	Completed **
-	NCT04325893	HCQ (124)	Placebo (123)	800 mg on day 1, then 400 mg/day for 8 days	Inpatient	≥18 years	6.88	France	Participant, Caregiver	1300	Recruiting
COV-HCQ	NCT04342221	HCQ (13)	Placebo (14)	800mg/day on day 1 and 600 mg/day for days 2-7	Inpatient	≥18 years	3.70	Germany	Participant, Caregiver	220	Recruiting
СОМІНҮ	NCT04340544	HCQ (8)	Placebo (8)	600mg/day for 7 days	Outpatient	≥18 years	0	Germany	Participant, Caregiver	2700	Recruiting

Abbreviations: chloroquine (CQ), hydroxychloroquine (HCQ)

\* Trial includes more treatment arms than reported here; target sample size refers to all arms. \*\* Other arms of the trial are still ongoing. \*\*\* Including centers in multiple countries. \*\*\*\* Including peer-reviewed journal publications and posted preprints.

	All trials	Included trials	Potentially eligible, unavailable trials*
	n = 62	n = 26	n = 36
Drug, n (%)			
HCQ	47 (76)	22 (85)	25 (69)
CQ	10 (16)	2 (8)	8 (22)
Both	5 (8)	2 (8)	3 (8)
Planned sample size*, median (IQR)	355 (150 to 693)	450 (212 to 1212)	308 (120 to 540)
Trial status, n (%)			
Completed	9 (15)	8 (31)	1 (3)
Discontinued	14 (23)	5 (19)	9 (25)
Not yet recruiting	7 (11)	0	7 (19)
Recruiting	32 (52)	13 (50)	19 (53)
Location, n (%)			
Africa	3 (5)	1 (4)	2 (6)
Asia	22 (35)	7 (27)	15 (42)
Europe	17 (27)	8 (31)	9 (25)
International	5 (8)	2 (8)	3 (8)
North America	10 (16)	4 (15)	6 (17)
Oceania	1 (2)	1 (4)	0
South America	4 (6)	3 (12)	1 (3)
Placebo control, n (%)	30 (48)	11 (42)	19 (53)
More than two arms, n (%)	27 (44)	9 (36)	18 (50)
Patient setting, n (%)			
ICU	1 (2)	1 (4)	0
Inpatient	45 (73)	20 (77)	25 (69)
Outpatient	12 (19)	5 (19)	7 (19)
Unclear	4 (6)	0	4 (11)
Blinding, n (%)			
None	31 (50)	13 (50)	18 (50)
Outcome Assessor	1 (2)	1 (4)	0
Participant	3 (5)	1 (4)	2 (6)
Participant, Caregiver	26 (42)	11 (42)	15 (42)
Participant, Outcome Assesso	r 1 (2)	0	1 (3)


 Table 2. Group-level characteristics of included and unavailable trials.

Abbreviations: chloroquine (CQ), hydroxychloroquine (HCQ), intensive care unit (ICU), interquartile range (IQR)

\* Data were extracted from trial registries or publications. \*\* Including centers in multiple countries.

## Figures

Figure 1. Flowchart of included randomized clinical trials.




Sources searched up to June 11, 2020 (PubMed, ClinicalTrials.gov, WHO ICTRP, Cochrane COVID Register) or April 9 (WHO Literature database, biorXiv, medrXiv, SwissEthics). <sup>1</sup> Trials for which we received no answer were presumed to be eligible unless withdrawn. <sup>2</sup> One publication and one preprint were identified in a later search update. <sup>3</sup> Published peer-reviewed articles or posted preprints. Abbreviations: chloroquine (CQ), hydroxychloroquine (HCQ), International Clinical Trials Registry Platform (ICTRP), World Health Organization (WHO). Figure 2A. Random effects meta-analysis for mortality for treatment of COVID-19 with Hydroxychloroquine, trials

are stratified by publication status.

Source	OR (S	95% CI)	Favours HCQ	Favours Control	Weight, %
Not Published OAHU-COVID19 ARCHAIC COV-HCQ NCT04335552 A NCT04353336 TEACH REMAP-CAP HYDRA NCT04325893 PROTECT B NCT04335552 B PROTECT A PATCH PROTECT C CCAP-1 NCT04333654 COMIHY	16.32 [0.03; 10 15.40 [0.16; 1 15.08 [0.01; 30 4.20 [0.04; 1.21 [0.36; 1.07 [0.34; 1.04 [0.49; 0.99 [0.51; 0.52 [0.19; 0.51 [0.04; 0.50 [0.01; 0.02 [0.00; 100	459.17] 501.97] 440.96] 4.12] 3.38] 2.18] 1.90] 1.45] 5.76] 19.56]			0.0 0.1 0.0 1.1 1.3 3.0 3.8 1.6 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Random subtotal (I²=0%)	0.96 [0.71;	1.29]	<	>	11.4
Published* Coalition I RECOVERY COVID-PEP NO COVID-19 NCT04384380 ChiCTR2000029868 NCT04261517 ChiCTR2000030054 BCN PEP CoV-2 Study ChiCTR2000029559	1.20 [0.40; 1.10 [0.96; 1.01 [0.06; 0.96 [0.06;	3.64] 1.26] 16.28] 16.22]			1.4 86.8 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Random subtotal (I <sup>2</sup> =0%)	1.10 [1.07;	1.13]			88.6
<b>Random effects model</b> Heterogeneity: $I^2 = 0\%$ , $\tau^2 = 0$ Test for overall effect: $p = 0.0$		<b>1.18]</b> 0	.1 0.2 0.5 1 Odds Ratio	6 1 2 5 10 5 (95% CI)	100.0

\* Published as peer-reviewed articles or posted preprints.

Figure 2B. Random effects meta-analysis for mortality for treatment of COVID-19 with Chloroquine.




The x-axis scales differ for reasons of readability.

Figure 3A. Cumulative meta-analysis for mortality for treatment of COVID-19 with Hydroxychloroquine.

Source	Favours HCQ	Favours Control	OR (95% CI)
Adding ChiCTR2000029559 (k=1) Adding ChiCTR2000029868 (k=2) Adding NCT04261517 (k=3) Adding RECOVERY (k=4) Adding ChiCTR2000030054 (k=5) Adding PATCH (k=6) Adding CCAP-1 (k=7) Adding NC COVID-19 (k=8) Adding NC T04335552 A (k=9) Adding NCT04335552 B (k=10) Adding NCT04335552 B (k=10) Adding NCT04333654 (k=12) Adding NCT04333654 (k=14) Adding NCT04333654 (k=14) Adding COVID-PEP (k=15) Adding BCN PEP CoV-2 Study (k=16) Adding NCT04353336 (k=17) Adding PROTECT C (k=18) Adding PROTECT A (k=19) Adding PROTECT B (k=20) Adding PROTECT B (k=20) Adding Coalition I (k=21) Adding TEACH (k=22) Adding NCT04325893 (k=25) Adding NCT04325893 (k=25) Adding COV-HCQ (k=26) Adding COMIHY (k=27) <b>Random effects model</b>			10 [0.96; 1.26] 10 [0.96; 1.26] 10 [0.96; 1.26] 10 [0.96; 1.26] 10 [1.01; 1.19] 10 [0.97; 1.24] 10 [1.00; 1.20] 10 [0.97; 1.25] 10 [0.97; 1.25] 10 [0.98; 1.22] 10 [0.98; 1.22] 10 [1.00; 1.20] 10 [1.00; 1.20] 10 [1.01; 1.19] 10 [1.01; 1.19] 10 [1.01; 1.19] 10 [1.01; 1.19] 10 [1.02; 1.18] 10 [1.02; 1.18] 10 [1.02; 1.18] 08 [0.99; 1.18] 08 [0.99; 1.18] 08 [0.99; 1.18]
C	).8 Odds Ratio	1 1.25 o (95% CI)	

Figure 3B. Cumulative meta-analysis for mortality for treatment of COVID-19 with Hydroxychloroquine

(publications and preprints only)



 $Figure \, 3C. \ Compare analysis for mortality for treatment of COVID-19 with Hydroxychloroquine$ 

(unpublished data only)

Source	Favours HCQ Fav	vours Control	OR (95% CI)
Adding PATCH (k=1) Adding CCAP-1 (k=2) Adding NCT04335552 A (k=3) Adding NCT04335552 B (k=4) Adding ARCHAIC (k=5) Adding HYDRA (k=6) Adding NCT04333654 (k=7) Adding NCT04353336 (k=8) Adding PROTECT C (k=9) Adding PROTECT A (k=10) Adding PROTECT B (k=11) Adding TEACH (k=12) Adding TEACH (k=12) Adding REMAP-CAP (k=14) Adding NCT04325893 (k=15)		4.20 1.13 [0 2.38 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	[0.04; 440.96] 0.00; 578132.00] [0.03; 208.12] 5 [0.46; 2.36] 5 [0.46; 2.36] 8 [0.62; 1.88] 8 [0.62; 1.88] 7 [0.66; 1.75] 3 [0.66; 1.61] 4 [0.73; 1.49] 6 [0.73; 1.53] 5 [0.79; 1.40] 5 [0.71; 1.29]
Adding COV-HCQ (k=16) Adding COMIHY (k=17)		0.90 0.90	6 [0.71; 1.29] 6 [0.71; 1.29]
Random effects model	0.001 0.1 1 10 Odds Ratio (95	1000	5 [0.71; 1.29]

The x-axis scales differ for reasons of readability.